Ameriprise’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-119,580
| Closed | -$2.6M | – | 3828 |
|
|
2017
Q2 | $2.6M | Buy |
119,580
+1,795
| +2% | +$32.6K | ﹤0.01% | 2479 |
|
|
2017
Q1 | $1.65M | Buy |
117,785
+2,234
| +2% | +$36.6K | ﹤0.01% | 2673 |
|
|
2016
Q4 | $2.17M | Buy |
115,551
+2,105
| +2% | +$35.8K | ﹤0.01% | 2576 |
|
|
2016
Q3 | $1.87M | Sell |
113,446
-17,360
| -13% | -$257K | ﹤0.01% | 2602 |
|
|
2016
Q2 | $1.76M | Buy |
130,806
+4,500
| +4% | +$65.6K | ﹤0.01% | 2589 |
|
|
2016
Q1 | $1.93M | Buy |
126,306
+3,348
| +3% | +$52.5K | ﹤0.01% | 2522 |
|
|
2015
Q4 | $2.44M | Sell |
122,958
-2,528
| -2% | -$48K | ﹤0.01% | 2482 |
|
|
2015
Q3 | $2.19M | Buy |
125,486
+12,448
| +11% | +$253K | ﹤0.01% | 2569 |
|
|
2015
Q2 | $2.29M | Buy |
113,038
+3,325
| +3% | +$64.2K | ﹤0.01% | 2670 |
|
|
2015
Q1 | $1.93M | Buy |
109,713
+4,831
| +5% | +$82.3K | ﹤0.01% | 2606 |
|
|
2014
Q4 | $1.71M | Buy |
104,882
+1,529
| +1% | +$28.1K | ﹤0.01% | 2625 |
|
|
2014
Q3 | $2.28M | Buy |
103,353
+23,030
| +29% | +$472K | ﹤0.01% | 2461 |
|
|
2014
Q2 | $1.62M | Buy |
80,323
+80,088
| +34,080% | +$1.36M | ﹤0.01% | 2607 |
|
|
2014
Q1 | $4K | Buy |
235
+5
| +2% | +$69 | ﹤0.01% | 4874 |
|
|
2013
Q4 | $2K | Sell |
230
-1,620
| -88% | -$19.6K | ﹤0.01% | 4910 |
|
|
2013
Q3 | $24K | Hold |
1,850
| – | – | ﹤0.01% | 4299 |
|
|
2013
Q2 | $22K | Buy |
+1,850
| New | +$20K | ﹤0.01% | 4220 |
|
Other funds holding AMRI
Ameriprise's AMRI Position: Q3 2017 in Review
Ameriprise sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 119,580 shares — an estimated $2.6M sold.
Ameriprise first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.6M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Ameriprise reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Ameriprise sold 119,580 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.6M.
- Ameriprise first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Ameriprise's Albany Molecular Research Inc position peaked at $2.6M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Ameriprise's 13F filing for Q3 2017, filed 7 Nov 2017.